NCT06567314View on ClinicalTrials.gov

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

September 1, 2028

Study Completion Date

September 1, 2030

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG

Ivonescimab

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Summit Therapeutics

All Listed Sponsors

collaborator

Summit Therapeutics

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER